AIM ImmunoTech (AIM) Change in Account Payables (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Change in Account Payables came in at -$415000.0 in Q1 2026, down 173.98% YoY from $561000.0 in Q1 2025, and down 641.07% on a QoQ basis from -$56000.0 in Q4 2025.
AIM ImmunoTech (AIM) Change in Account Payables (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of Change in Account Payables data on file, last reported at -$415000.0 in Q1 2026.
- Quarterly Change in Account Payables fell 173.98% year-over-year to -$415000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.7 million (down 813.0% YoY) and the FY2025 annual result came in at -$1.7 million, down 2753.33% from the prior year.
- Change in Account Payables eased to -$415000.0 in Q1 2026, from -$56000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $3.7 million in Q4 2023 to a low of -$2.6 million in Q3 2025.
- A 5-year average of $238705.9 and a median of $244000.0 in 2022 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2023 — Change in Account Payables surged 731.26% — and 2025, when it plunged 417.68%.
- Tracing AIM's Change in Account Payables over 5 years: stood at -$579000.0 in 2022, then soared by 731.26% to $3.7 million in 2023, then plunged by 96.74% to $119000.0 in 2024, then tumbled by 147.06% to -$56000.0 in 2025, then plunged by 641.07% to -$415000.0 in 2026.
- The last three Change in Account Payables figures came in at -$415000.0 (Q1 2026), -$56000.0 (Q4 2025), and -$2.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | AIM ImmunoTech | 4.43 Mn | -5.53 Mn | 21,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -415,000.00 |
| Mar 31, 2026 | -415,000.00 |
| Dec 31, 2025 | -56,000.00 |
| Dec 31, 2025 | -56,000.00 |
| Sep 30, 2025 | -2.57 Mn |
| Sep 30, 2025 | -2.57 Mn |
| Jun 30, 2025 | 353,000.00 |
| Jun 30, 2025 | 353,000.00 |
| Mar 31, 2025 | 561,000.00 |
| Mar 31, 2025 | 561,000.00 |
| Dec 31, 2024 | 119,000.00 |
| Dec 31, 2024 | 119,000.00 |
| Sep 30, 2024 | 809,000.00 |
| Sep 30, 2024 | 809,000.00 |
| Jun 30, 2024 | -1.11 Mn |
| Jun 30, 2024 | -1.11 Mn |
| Mar 31, 2024 | 124,000.00 |
| Mar 31, 2024 | 124,000.00 |
| Dec 31, 2023 | 3.66 Mn |
| Dec 31, 2023 | 3.66 Mn |